Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.67 |
| ▸ | HTR2A | P28223 | 8/20 | 0.67 |
| ▸ | HTR2B | P41595 | 8/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940018 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BHRH3MAOB | |
| Hydrochloric Acid SCHEMBL4937772 | 0.99 | HTR2C (0.66) | HTR2CHTR2AHTR2BHRH3MAOB | |
| Hydrochloric Acid SCHEMBL4929497 | 0.99 | HTR2C (0.66) | HTR2CHTR2AHTR2BHRH3MAOB | |
| Hydrochloric Acid SCHEMBL4937777 | 0.99 | HTR2C (0.66) | HTR2CHTR2AHTR2BHRH3MAOB | |
| SCHEMBL5442260 | 0.91 | HTR2C (0.65) | HTR2CHTR2AHTR2BHRH3MAOB | |
| SCHEMBL5442266 | 0.91 | HTR2C (0.65) | HTR2CHTR2AHTR2BHRH3MAOB | |
| SCHEMBL5442264 | 0.91 | HTR2C (0.65) | HTR2CHTR2AHTR2BHRH3MAOB | |
| SCHEMBL4933088 | 0.88 | HTR2C (0.58) | HTR2CHTR2AHTR2BMAOBMAOA | |
| SCHEMBL4933084 | 0.88 | HTR2C (0.58) | HTR2CHTR2AHTR2BMAOBMAOA | |
| SCHEMBL4933090 | 0.88 | HTR2C (0.58) | HTR2CHTR2AHTR2BMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | HTR2C 1/4885HTR2A 2/4885HTR2B 3/4885 |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | HTR2C 1/4885HTR2A 2/4885HTR2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.